# Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway Inhibitor

Source: https://onco.cc/trials/nct04416516/  
OnCo record `nct04416516` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of SP-002 run by Ascend Biopharmaceuticals Ltd, completed.

## Summary

Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway Inhibitor is a phase 2 interventional study registered as NCT04416516 by Ascend Biopharmaceuticals Ltd, with 21 participants enrolled, started 2020-07-16. Conditions recorded: Basal Cell Carcinoma and Basal Cell Nevus Syndrome. Interventions recorded: ASN-002.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04416516
- Phase: 2
- Setting: A Phase 2A Study to Assess the Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway Inhibitor in the Treatment of Multiple Low Risk Basal Cell Carcinomas in Sporadic or Basal Cell Nevus Syndrome Patients
- Sponsor: Ascend Biopharmaceuticals Ltd
- Enrolled: 21

## Sources

- ClinicalTrials.gov NCT04416516: https://clinicaltrials.gov/study/NCT04416516

## Connected records

- cancers: [Basal cell carcinoma](https://onco.cc/cancers/basal-cell-carcinoma/)
- drugs: [SP-002](https://onco.cc/drugs/sp-002/)
- companies: [Stamford Pharmaceuticals](https://onco.cc/companies/stamford-pharmaceuticals/)

---
JSON: https://onco.cc/api/v1/entities/nct04416516.json